Prospects for "EuroNICE" and a single European pharma pricing market

13 July 2008

Despite a current void, increasing ties between pricing and reimbursement authorities across Europe through reference pricing and cost-effectiveness show a clear momentum towards regulatory harmonization. Global Insight examines the scope and potential for a single European pricing market.

- There are already significant processes and institutions in place to create a single European pricing and reimbursement (P&R) market. The European Commission, alongside the European Union price transparency directive and information-sharing for cost-effectiveness, is the primary source for potential institution-building.

- The vast network of parallel trading and international reference pricing ensures that Europe is already a significantly harmonised market, although each country has a deeply engrained national health care system.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight